MAIA Biotechnology, Inc. financial data

Symbol
MAIA on NYSE
Location
Chicago, IL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 07 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 187% % -15%
Debt-to-equity 259% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37,032,307 shares 46%
Common Stock, Shares, Outstanding 34,451,153 shares 44%
Entity Public Float $67,463,300 USD 200%
Common Stock, Value, Issued $3,446 USD 44%
Weighted Average Number of Shares Outstanding, Basic 33,202,001 shares 39%
Weighted Average Number of Shares Outstanding, Diluted 33,202,001 shares 39%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $10,886,019 USD -3.1%
General and Administrative Expense $9,322,246 USD 23%
Operating Income (Loss) $24,957,019 USD -36%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $8,903,189 USD -225%
Earnings Per Share, Basic 0 USD/shares 50%
Earnings Per Share, Diluted 0 USD/shares 50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $0 USD
Assets, Current $11,754,936 USD 27%
Other Assets, Noncurrent $27,085 USD 867%
Assets $11,782,021 USD 27%
Accounts Payable, Current $3,175,641 USD 176%
Accrued Liabilities, Current $6,818,803 USD 178%
Liabilities, Current $9,994,444 USD 177%
Liabilities $11,740,351 USD 54%
Accumulated Other Comprehensive Income (Loss), Net of Tax $30,835 USD -164%
Retained Earnings (Accumulated Deficit) $106,002,244 USD -27%
Stockholders' Equity Attributable to Parent $41,670 USD -97%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $4,942,525 USD
Liabilities and Equity $11,782,021 USD 27%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,202,274 USD -17%
Net Cash Provided by (Used in) Financing Activities $5,461,216 USD 16%
Common Stock, Shares Authorized 150,000,000 shares 114%
Common Stock, Shares, Issued 34,451,153 shares 44%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,261,998 USD 13%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,863,296 USD 31%
Deferred Tax Assets, Valuation Allowance $15,188,160 USD 46%
Deferred Tax Assets, Gross $15,188,160 USD 46%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $22,358,482 USD 14%
Deferred Tax Assets, Operating Loss Carryforwards $8,238,806 USD 58%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30,000,000 shares 0%
Additional Paid in Capital $106,071,303 USD 24%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $2,514,299 USD -2.6%
Interest Expense $85 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%